Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 671 to 680 of 2440 total matches.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes ...
...
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
mg/50 mL singledose
vials. The recommended dosage is 15 mg/kg
infused IV over 60 minutes on days 1 ...
Olaratumab (Lartruvo – Lilly), a platelet-derived growth
factor receptor alpha (PDGFR-α) blocking monoclonal
antibody, has received accelerated approval from the
FDA for use in combination with the anthracycline
doxorubicin for first-line treatment of adults with
soft-tissue sarcoma histologic subtypes considered
susceptible to anthracyclines. Approval is limited to
locally advanced or metastatic soft-tissue sarcomas
that are not amenable to curative radiotherapy or
surgery, and is contingent on verification of clinical
benefit in a confirmatory phase 3 trial.
In Brief: Midostaurin (Rydapt) for AML and Advanced Systemic Mastocytosis (online only)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
0.78). The
4-year overall survival rate was 51.4% with midostaurin and
44.3% with placebo.1 Common ...
The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML). About 30% of patients with AML have FLT3 mutations. Midostaurin is also approved as a single agent for treatment of adults with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast-cell leukemia. In mastocytosis, midostaurin targets mutant c-KIT, not FLT3.In a randomized, double-blind trial, 717...
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jul 31, 2017 (Issue 1526)
” is replaced with “focal” and
“primary generalized" with “bilateral tonic-clonic.”1
BRIVARACETAM ...
Treatment of epilepsy should begin with a single
antiepileptic drug (AED), increasing its dosage
gradually until seizures are controlled or adverse
effects become intolerable. If seizures persist,
specialists generally recommend trying at least
one and sometimes a second alternative drug as
monotherapy before considering use of two drugs
concurrently. When used for the appropriate seizure
type, AEDs are roughly equivalent in efficacy. Drug
choice is usually based on factors such as ease of
use, adverse effects, drug interactions, presence of
comorbidities, and cost.
Comparison Table: Some Oral Antiepileptic Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Jul 31, 2017 (Issue 1526)
tablet; SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis
1. Most antiepileptic drugs ...
View the Comparison Table: Some Oral Antiepileptic Drugs
Drugs for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
-associated
lymphoid tissue (MALT) lymphoma.1 Eradication of H.
pylori can promote gastric healing, prevent ...
About 50% of the world’s population is infected with
Helicobacter pylori. These gastric bacteria can cause
chronic inflammation and have been associated with
development of gastritis, peptic ulcer disease, gastric
adenocarcinoma, and gastric mucosa-associated
lymphoid tissue (MALT) lymphoma. Eradication of H.
pylori can promote gastric healing, prevent recurrence
of duodenal and gastric ulcers, and reduce the
incidence of gastric cancer. Guidelines for treatment
of H. pylori infection were updated recently.
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
earlier.1,2
STANDARD TREATMENT — Plaque psoriasis is
a chronic, inflammatory, immune-mediated skin ...
The FDA has approved brodalumab (Siliq – Valeant),
an injectable human interleukin (IL)-17A receptor
antagonist, for treatment of adults with moderate to
severe plaque psoriasis who have failed to respond
to other systemic therapies. Brodalumab is the third
IL-17A antagonist to be approved in the US for this
indication; secukinumab (Cosentyx) and ixekizumab
(Taltz) were approved earlier.
In Brief: Avelumab (Bavencio) for Metastatic Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
-human programmed death
ligand 1 (PD-L1) blocking antibody avelumab (Bavencio –
EMD Serono/Pfizer ...
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12 years old. Avelumab is the first drug to be approved in the US for this rare skin cancer. About 1600 people in the US, most commonly older adults (mean age at presentation is 75 years), are diagnosed each year with MCC. Most of these patients can be treated with surgical resection, but ~50% will have a recurrence and >30% will eventually have metastatic disease. Median progression-free...
Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
syndrome occurs
in about 20% of patients with neuroendocrine
tumors.1 It is characterized by diarrhea ...
The FDA has approved telotristat ethyl (Xermelo –
Lexicon), a tryptophan hydroxylase inhibitor, for
use in combination with a somatostatin analog
(SSA) for treatment of carcinoid syndrome diarrhea
inadequately controlled with SSA therapy alone.
Telotristat ethyl is the first oral drug to be approved
in the US for this indication.
Ocrelizumab (Ocrevus) for MS
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017 (Issue 1523)
of symptom onset.1,2
Pronunciation Key
Ocrelizumab: oc” re liz’ ue mab Ocrevus: oak' rev us
Primary ...
The FDA has approved ocrelizumab (Ocrevus –
Genentech), a humanized anti-CD20 monoclonal
antibody, for treatment of adults with primary
progressive or relapsing multiple sclerosis (MS). It is the
first anti-CD20 monoclonal antibody to be approved for
treatment of MS and the first disease-modifying drug
to be approved in the US for primary progressive MS.